Zhonghua bing li xue za zhi = Chinese journal of pathology
Guideline for HER2 testing in breast cancer (2024 version)
Abstract
随着抗HER2靶向治疗的进展及循证依据的更新，HER2检测与诊断亟需进一步规范和标准化。因此，本指南基于《乳腺癌HER2检测指南（2019版）》，围绕10个主要相关问题进行了全面覆盖，特别详述了HER2诊断流程和报告内容（包括HER2低/超低表达）、HER2异质性、质量控制流程优化，以及人工智能技术在乳腺癌HER2检测中的应用前景，旨在提高HER2检测的准确性和可重复性，为临床抗HER2靶向治疗策略提供有力支持。.
Source and rights
Published by Zhonghua bing li xue za zhi = Chinese journal of pathology, 2024. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
More in oncology
- Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyNational Comprehensive Cancer Network · 2026
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance) [2] · 2026
